EMA Product Specific GL [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2017-07-28 14:40 (3257 d 11:54 ago) – Posting: # 17620
Views: 10,432

Dear all,

a new set of product-specific guidances was adopted by CHMP for public consultation on 22 June (published on 28 July [1–4], 3 August [5–7]). Deadline for comments: 31 October.
  1. Dolutegravir film-coated tablets 10 mg, 25 mg and 50 mg
  2. Dronedarone film-coated tablets 400 mg
  3. Paracetamol oral use, immediate release formulations
  4. Rilpivirine film-coated tablets 25 mg
  5. Dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg
  6. Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg
  7. Tadalafil film-coated tablets 2.5 mg, 5 mg, 10 mg and 20 mg
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
340 visitors (0 registered, 340 guests [including 18 identified bots]).
Forum time: 02:34 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5